The Relative Strength (RS) Rating for Kymera Therapeutics headed into a higher percentile Thursday, as it got a lift from 69 to 76.
How To Invest In Stocks In Both Bull And Bear Markets
IBD's proprietary RS Rating measures market leadership by using a 1 (worst) to 99 (best) score that identifies how a stock's price performance over the last 52 weeks matched up against all other stocks.
Decades of market research shows that the top-performing stocks typically have an 80 or better RS Rating in the early stages of their moves. See if Kymera Therapeutics can continue to rebound and clear that threshold.
While Kymera Therapeutics is not near an ideal buy zone right now, see if it is able to form and break out of a proper consolidation.
Kymera Therapeutics showed 0% EPS growth in the latest quarterly report, while sales growth came in at -55%.
Kymera Therapeutics earns the No. 300 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Incyte are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
